H.C. Wainwright raised the firm’s price target on Humacyte (HUMA) to $12 from $6 and keeps a Buy rating on the shares. The firm raised its pricing forecast to Humacyte’s Acellular Tissue Engineered Vessel to $50,000 from $25,000.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte announces reuslts from V007 Phase 3 trial of ATEV in AV
- Humacyte to host KOL event on he use of ATEV for AV access in hemodialysis
- Hertz Global Holdings call volume above normal and directionally bullish
- Unusually active option classes on open October 18th
- Humacyte issues raised in 483 appear ‘fixable,’ says BTIG